New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
September 29, 2010
11:16 EDTWDC, CSTR, MNKD, DELL, LLY, BCSIOn The Fly: Rumor Buzz
Market speculation today includes takeover chatter involving Coinstar (CSTR)...Blue Coat Systems (BCSI) advances about 4.9% and is again the subject of an unconfirmed takeover rumor. Dell (DELL) has previously been mentioned as a possible suitor...Western Digital Corp. (WDC) is up almost 3.5% on renewed takeover speculation...Unconfirmed is a rumor that Eli Lilly & Co. (LLY) is readying a $12.50 bid for MannKind Corp. (MNKD), up 2.9%.
News For CSTR;BCSI;DELL;WDC;LLY;MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
13:02 EDTLLYEli Lilly says trial data shows Trulicity effective as add-on treatment
New data from a completed Phase 3 trial show Trulicity 1.5 mg plus a sulfonylurea was significantly more effective than a sulfonylurea alone in lowering hemoglobin A1C from baseline after 24 weeks of treatment, Eli Lilly said. Trulicity is Eli Lilly's once-weekly glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes. These data, from the Trulicity AWARD-8 clinical trial, were presented for the first time today at the 2015 International Diabetes Federation World Diabetes Congress in Vancouver, Canada. "For patients who cannot tolerate or have contraindications to metformin, a sulfonylurea is often prescribed as first-line therapy for type 2 diabetes," said Kathleen Dungan, M.D., endocrinologist, associate professor, The Ohio State University Wexner Medical Center, and lead study author. "This study affirms that Trulicity is efficacious and well-tolerated as an add-on to sulfonylurea therapy, which can help prescribers make treatment decisions for their individual patients."
10:00 EDTLLYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded to Outperform from Neutral at Credit Suisse... Allstate (ALL) upgraded to Neutral from Sell at Citi... Campbell Soup (CPB) upgraded to Buy from Hold at Argus... Cenovus Energy (CVE) upgraded to Neutral from Sell at Goldman... Computer Programs (CPSI) upgraded to Hold from Sell at Deutsche Bank... Concho Resources (CXO) upgraded to Strong Buy from Outperform at Raymond James... Conn's (CONN) upgraded to Buy from Hold at Stifel... Delta Lloyd (DLLLY) upgraded to Neutral from Underweight at JPMorgan... Eli Lilly (LLY) assumed with an Overweight from Equal Weight at Barclays... HF Financial (HFFC) upgraded to Buy from Hold at Sandler O'Neill... Johnson & Johnson (JNJ) upgraded to Overweight from Equal Weight at Barclays... KPN (KKPNY) upgraded to Buy from Neutral at Nomura... Merck (MRK) assumed with an Overweight from Equal Weight at Barclays... Monsanto (MON) upgraded to Overweight from Neutral at Atlantic Equities... Nokia (NOK) upgraded to Outperform from Neutral at Credit Suisse... Parkway Properties (PKY) upgraded to Buy from Hold at Stifel... Pioneer Natural (PXD) upgraded to Strong Buy from Outperform at Raymond James... Rackspace (RAX) upgraded to Outperform from Sector Perform at RBC Capital... TerraForm Power (TERP) upgraded to Outperform from Perform at Oppenheimer... Windstream (WIN) upgraded to Outperform from Market Perform at Raymond James... Yum! Brands (YUM) upgraded to Outperform from Market Perform at Cowen.
09:34 EDTLLYBarclays biopharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information
05:43 EDTLLYEli Lilly assumed with an Overweight from Equal Weight at Barclays
Barclays analyst Geoff Meacham upgraded Eli Lilly (LLY) to Overweight after assuming coverage of the name. Good execution for Cyramza and Jardiance should drive continued share outperformance, Meacham tells investors in a research note. He raised his price target for shares to $95 from $75. Lilly closed yesterday down $1.43 to $82.22. The analyst this morning also upgraded Johnson & Johnson (JNJ) and Merck (MRK) to Overweight and downgraded AbbVie (ABBV) to Equal Weight.
November 29, 2015
12:57 EDTWDCHigh-yield tech stocks could offer significant returns, Barron's says
Growth-focused investors have piled into Facebook (FB), Alphabet (GOOG, GOOGL), Salesforce (CRM), and others, but if the "current situation" changes, high-yield stocks with compelling valuations could grab some of the spotlight, Barron's contends in a feature story. The publication names Seagate (STX), Garmin (GRMN), Qualcomm (QCOM), Hewlett-Packard (HPQ), IBM (IBM), and Western Digital (WDC) as attractive plays, noting that their dividends -- ranging 3.2% to 7.3% -- look secure and offer nice rewards for those willing to wait for potential turnarounds or strategic transactions. Reference Link
November 24, 2015
14:43 EDTLLYEli Lilly confirms FDA approval of Portrazza
Subscribe for More Information
11:48 EDTLLYFDA approves Portrazza to treat NSCLC
Subscribe for More Information
November 20, 2015
08:08 EDTMNKDMannKind CEO steps down, Alfred Mann appointed as interim CEO
MannKind announced that Hakan Edstrom has stepped down as the president, CEO and as a director of MannKind. The board of MannKind appointed Alfred Mann as interim CEO, effective November 19. Mann will continue to serve as the Executive Chairman of the company. A committee of the board will commence an immediate search for a successor CEO.
November 19, 2015
06:34 EDTLLYEli Lilly, Merck expand immuno-oncology collaboration
Eli Lilly (LLY) and Merck (MRK) announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lilly's Alimta and Merck's Keytruda in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer, or NSCLC. The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Financial details of the collaboration were not disclosed. The expansion of this oncology clinical trial collaboration comes following the release of encouraging data from a Phase I study, presented earlier this year at the 16th World Congress on Lung Cancer, which evaluated pemetrexed, carboplatin and pembrolizumab in first-line nonsquamous NSCLC.
November 18, 2015
08:11 EDTLLYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
06:09 EDTLLYValeant's Addyi sees hardly any sales, Bloomberg says
Subscribe for More Information
November 17, 2015
11:10 EDTWDCMicron the most likely target for Tsinghua stake, says Macquarie
Macquarie analyst Deepon Nag highlighted yesterday that Tsinghua Unigroup Chairman Zhao Weiguo told Reuters in an interview that his company was in talks with a U.S. semiconductor company, and that a deal could be announced as early as the end of the month. Zhao stated that a majority stake was unlikely due to regulatory concerns. Given recent moves by China in the memory market, Micron (MU) is the most likely target for Tsinghua, Nag wrote in a note to investors. Tsinghua recently announced a 15% stake in Western Digital (WDC) at a 33% premium to the company's prior closing price. A similar premium for Micron would lead to a 15% stake in Micron for $20 per share, which would equal $3.4B, the analyst points out. Shares of Micron are up 46c, or 3%, to $15.35 in late morning trading. Nag has an Outperform rating on Micron with a $30 price target.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use